Last reviewed · How we verify
Azithromycin for Oral Suspension
At a glance
| Generic name | Azithromycin for Oral Suspension |
|---|---|
| Also known as | Zithromax |
| Sponsor | University of California, San Francisco |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex (PHASE3)
- Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease (PHASE2)
- Azithromycin as Adjunctive Treatment for Uncomplicated Severe Acute Malnutrition (PHASE4)
- A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events
- Azithromycin for Child Survival in Niger II (PHASE4)
- Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old Infants in Mali (PHASE3)
- Azithromycin for Child Survival in Niger: Mortality and Resistance Trial (PHASE4)
- Azithromycin for Child Survival in Niger: Delivery Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: